Severe hypocalcaemia after denosumab and intravenous iron: a cautionary tale

Intern Med J. 2023 Nov;53(11):2139-2140. doi: 10.1111/imj.16261.

Authors

Laura Cuthbertson¹, Alice Morris², Richard Yu¹

Affiliations

¹ Department of Nephrology, Royal Hobart Hospital, Hobart, Tasmania, Australia.
² Department of General Medicine, Royal Hobart Hospital, Hobart, Tasmania, Australia.

PMID: 37997270
DOI: 10.1111/imj.16261

No abstract available

Publication types

Letter

MeSH terms

Bone Density Conservation Agents* / adverse effects
Calcium
Denosumab / adverse effects
Humans
Hypocalcemia* / chemically induced
Hypocalcemia* / diagnosis
Iron / adverse effects

Substances

Denosumab
Iron
Bone Density Conservation Agents
Calcium